Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer's disease

American Journal of Alzheimer's Disease and other Dementias

Volumn 27, Issue 6, 2012, Pages 421-432

  Salloway, Stephen ^a   Mintzer, Jacobo ^b,c   Cummings, Jeffrey L ^d   Geldmacher, David ^e   Sun, Yijun ^f   Yardley, Jane ^g   MacKell, Joan ^h  

^a BROWN UNIVERSITY   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^d CLEVELAND CLINIC LOU RUVO CENTER FOR BRAIN HEALTH   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f EISAI INC   (United States)

^g EISAI CO LTD   (Japan)

^h PFIZER INC   (United States)

Author keywords

Alzheimer's disease; clinical trial; donepezil; efficacy; tolerability; United States

Indexed keywords

DONEPEZIL; MEMANTINE;

AGITATION; ALZHEIMER DISEASE; ANOREXIA; ANXIETY; APHASIA; ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HUMAN; HYPERTENSION; PHYSICIAN; PNEUMONIA; PRESYNCOPE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SYNCOPE; UNITED STATES; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; URINE INCONTINENCE; VOMITING; WEIGHT;

EID: 84865619371     PISSN: 15333175     EISSN: 19382731     Source Type: Journal    
DOI: 10.1177/1533317512454708     Document Type: Article

References (19)

1. Black SE, Doody R, Li H, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology. 2007 ; 69 (5). 459-469 (Pubitemid 47450281)
2. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology. 2001 ; 57 (4). 613-620 (Pubitemid 32782987)
3. Seltzer B, Zolnouni P, Nunez M, et al. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. Arch Neurol. 2004 ; 61 (12). 1852-1856 (Pubitemid 39612945)
4. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001 ; 57 (3). 489-495 (Pubitemid 32757598)
5. Winblad B, Kilander L, Eriksson S, et al. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet. 2006 ; 367 (9516). 1057-1065
6. Farlow MR, Salloway S, Tariot PN, et al. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: a 24-week, randomized, double-blind study. Clin Ther. 2010 ; 32 (7). 1234-1251
7. FDA Center for Drug Evaluation and Research. Summary Review for Aricept (donepezil hydrochloride extended release) 23 mg Sustained Release. 2012.
8. Schmitt FA, Cragar D, Ashford JW, et al. Measuring cognition in advanced Alzheimer's disease for clinical trials. J Neural Transm Suppl. 2002 ; (62). 135-148 (Pubitemid 37046661)
9. Sabbagh M, Cummings J. Progressive cholinergic decline in Alzheimer's disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology. BMC Neurol. 2011 ; 11: 21
10. Scarmeas N, Albert SM, Manly JJ, Stern Y. Education and rates of cognitive decline in incident Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2006 ; 77 (3). 308-316
11. Stern Y, Albert S, Tang MX, Tsai WY. Rate of memory decline in AD is related to education and occupation: cognitive reserve?. Neurology. 1999 ; 53 (9). 1942-1947
12. Whitehair DC, Sherzai A, Emond J, et al. Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairment. Alzheimers Dement. 2010 ; 6 (5). 412-419
13. Caselli RJ, Reiman EM, Locke DE, et al. Cognitive domain decline in healthy apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive impairment. Arch Neurol. 2007 ; 64 (9). 1306-1311 (Pubitemid 47403086)
14. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005 ; 352 (23). 2379-2388 (Pubitemid 40958434)
15. Inglis F.. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int J Clin Pract Suppl. 2002 ; (127). 45-63 (Pubitemid 34778530)
16. Rosenblatt A, Gao J, Mackell J, Richardson S. Efficacy and safety of donepezil in patients with Alzheimer's disease in assisted living facilities. Am J Alzheimers Dis Other Demen. 2010 ; 25 (6). 483-489
17. Doody RS, Ferris S, Salloway S, et al. Safety and tolerability of donepezil in mild cognitive impairment: open-label extension study. Am J Alzheimers Dis Other Demen. 2010 ; 25 (2). 155-159
18. Feldman HH, Woodward M. The staging and assessment of moderate to severe Alzheimer disease. Neurology. 2005 ; 65: S10 - S17
19. Rammes G, Rupprecht R, Ferrari U, Zieglgansberger W, Parsons CG. The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci Lett. 2001 ; 306 (1-2). 81-84 (Pubitemid 32524303)